The Prognostic Value of Residual Disease in Ovarian Cancer
Authors: Sabrina Serani & Amir Jazaeri, MD
Fact checked by: Jason M. Broderick
August 22, 2025
Key Takeaways
- SLL and ctDNA are effective in detecting MRD in ovarian cancer, surpassing conventional methods like CA 125 and CT scans.
- SLL provides access to MRD tissue, offering insights into chemoresistance and potential therapeutic targets.
- CtDNA is a promising early surrogate endpoint in clinical trials, allowing earlier assessment of treatment efficacy.
- Identifying high-risk patients through these methods enables earlier intervention with innovative and investigational therapies.
UPDATES AND NEWS
Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working | The New York Times
We can prevent ovarian cancer. Women deserve the option. | USA Today
Fallopian tube removal may lower ovarian cancer risk | Good Morning America
The Lustgarten Foundation and Break Through Cancer Announce New Clinical Trial Evaluating KRAS-targeted Immunotherapy Strategy for Pancreatic Cancer
BE PART OF THE MISSION
Stay Informed, Make an Impact
Subscribe
Be the first to hear about cutting-edge research, pioneering projects, and the latest advancements in Break Through Cancer science. Sign up to stay informed.
Give
Your contribution fuels groundbreaking research in some of the most challenging cancers. Every gift accelerates progress. For more information please contact Michaela Forand at MF@breakthroughcancer.org or 1-800-757-9881 ext 2.
